1. Home
  2. MLYS vs AHL Comparison

MLYS vs AHL Comparison

Compare MLYS & AHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • AHL
  • Stock Information
  • Founded
  • MLYS 2019
  • AHL 2002
  • Country
  • MLYS United States
  • AHL Bermuda
  • Employees
  • MLYS N/A
  • AHL N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • AHL Property-Casualty Insurers
  • Sector
  • MLYS Health Care
  • AHL Finance
  • Exchange
  • MLYS Nasdaq
  • AHL Nasdaq
  • Market Cap
  • MLYS 2.9B
  • AHL 3.4B
  • IPO Year
  • MLYS 2023
  • AHL 2025
  • Fundamental
  • Price
  • MLYS $40.40
  • AHL $36.98
  • Analyst Decision
  • MLYS Strong Buy
  • AHL Buy
  • Analyst Count
  • MLYS 6
  • AHL 8
  • Target Price
  • MLYS $46.40
  • AHL $39.44
  • AVG Volume (30 Days)
  • MLYS 1.5M
  • AHL 257.5K
  • Earning Date
  • MLYS 11-10-2025
  • AHL 11-13-2025
  • Dividend Yield
  • MLYS N/A
  • AHL N/A
  • EPS Growth
  • MLYS N/A
  • AHL 33.46
  • EPS
  • MLYS N/A
  • AHL 6.60
  • Revenue
  • MLYS N/A
  • AHL $3,191,700,000.00
  • Revenue This Year
  • MLYS N/A
  • AHL N/A
  • Revenue Next Year
  • MLYS N/A
  • AHL $8.12
  • P/E Ratio
  • MLYS N/A
  • AHL $5.59
  • Revenue Growth
  • MLYS N/A
  • AHL 5.65
  • 52 Week Low
  • MLYS $8.24
  • AHL $27.05
  • 52 Week High
  • MLYS $47.65
  • AHL $37.03
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 49.69
  • AHL N/A
  • Support Level
  • MLYS $36.56
  • AHL N/A
  • Resistance Level
  • MLYS $47.65
  • AHL N/A
  • Average True Range (ATR)
  • MLYS 3.45
  • AHL 0.00
  • MACD
  • MLYS -0.00
  • AHL 0.00
  • Stochastic Oscillator
  • MLYS 50.18
  • AHL 0.00

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About AHL Aspen Insurance Holdings Limited Class A Ordinary Shares

Aspen Insurance Holdings Ltd is a Bermudian insurance and reinsurance company. Its principal business is marketing and underwriting specialty insurance and reinsurance regularly. It comprises underwriting operations, which include risk-bearing insurance and reinsurance operations; Investing activities, which support underwriting operations; and ACM operations, which earn underwriting, management, and performance fees. It has two segments: Aspen Insurance and Aspen Reinsurance. Aspen Insurance consists of property and casualty insurance, marine, aviation, and energy insurance, and financial and professional lines insurance. Aspen Reinsurance comprises property catastrophe reinsurance, other property reinsurance, casualty reinsurance, and specialty reinsurance.

Share on Social Networks: